文献速递妇科肿瘤

MILO/ENGOT-ov11:比美替尼对比医生选择化疗治疗复发性低级别浆液性卵巢癌

MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
PubMed 文献 · J Clin Oncol · 2020-08-21

该2:1随机研究比较比美替尼与医生选择化疗在复发性低级别浆液性卵巢癌中的疗效,主要终点盲法独立中心评估的无进展生存期未达标(9.1个月 vs 10.6个月,HR 1.21),研究因预设无效边界提前关闭,但比美替尼在多个疗效终点显示活性,KRAS突变可能与比美替尼应答相关。

要点

  • 比美替尼组中位PFS 9.1个月,化疗组10.6个月,HR 1.21,未达主要终点。
  • 两组ORR分别为16%与13%,中位OS分别为25.3与20.8个月。
  • KRAS突变可能与比美替尼应答相关,需进一步验证。

核心结论

  • 研究未达到主要终点,但比美替尼在低级别浆液性卵巢癌中跨疗效终点显示活性。
  • 化疗应答率高于预期,KRAS突变可能预测比美替尼应答。

研究设计与样本

  • 2:1随机研究,比较比美替尼45mg每日两次与医生选择化疗。
  • 入组复发性可测量低级别浆液性卵巢癌患者,既往至少1线但不超过3线化疗。
  • 主要终点为盲法独立中心评估的无进展生存期。

主要发现

  • 中位PFS:比美替尼9.1个月(95%CI 7.3-11.3),化疗10.6个月(95%CI 9.2-14.5),HR 1.21(95%CI 0.79-1.86)。
  • ORR:比美替尼16%(32例CR/PR),化疗13%(13例CR/PR)。
  • 中位DOR:比美替尼8.1个月(范围0.03至≥12.0),化疗6.7个月(范围0.03至≥9.7)。
  • 中位OS:比美替尼25.3个月,化疗20.8个月。
  • 最常见≥3级不良事件为血肌酸激酶升高(26%)。

关键数值与推荐

  • 因预设无效边界,在入组341例后研究提前关闭。
  • 事后分析提示KRAS突变与比美替尼应答可能存在关联。

临床怎么用

  • 比美替尼未优于医生选择化疗,不作为复发性低级别浆液性卵巢癌的首选常规治疗。
  • KRAS突变状态可能有助于筛选比美替尼潜在获益人群。

局限性

  • 研究因无效边界提前关闭,统计效能可能受限。
  • 事后分析结果需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Low-grade serous ovarian carcinomas (LGSOCs) have historically low chemotherapy responses. Alterations affecting the MAPK pathway, most commonly KRAS/BRAF, are present in 30%-60% of LGSOCs. The purpose of this study was to evaluate binimetinib, a potent MEK1/2 inhibitor with demonstrated activity across multiple cancers, in LGSOC. METHODS: This was a 2:1 randomized study of binimetinib (45 mg twice daily) versus physician's choice chemotherapy (PCC). Eligible patients had recurrent measurable LGSOC after ≥ 1 prior platinum-based chemotherapy but ≤ 3 prior chemotherapy lines. The primary end point was progression-free survival (PFS) by blinded independent central review (BICR); additional assessments included overall survival (OS), overall response rate (ORR), duration of response (DOR), clinical-benefit rate, biomarkers, and safety. RESULTS: A total of 303 patients were randomly assigned to an arm of the study at the time of interim analysis (January 20, 2016). Median PFS by BICR was 9.1 months (95% CI, 7.3 to 11.3) for binimetinib and 10.6 months (95% CI, 9.2 to 14.5) for PCC (hazard ratio,1.21; 95%CI, 0.79 to 1.86), resulting in early study closure according to a prespecified futility boundary after 341 patients had enrolled. Secondary efficacy end points were similar in the two groups: ORR 16% (complete response [CR]/partial responses[PRs], 32) versus 13% (CR/PRs, 13); median DOR, 8.1 months (range, 0.03 to ≥ 12.0 months) versus 6.7 months (0.03 to ≥ 9.7 months); and median OS, 25.3 versus 20.8 months for binimetinib and PCC, respectively. Safety results were consistent with the known safety profile of binimetinib; the most common grade ≥ 3 event was increased blood creatine kinase level (26%). Post hoc analysis suggests a possible association between KRAS mutation and response to binimetinib. Results from an updated analysis (n = 341; January 2019) were consistent. CONCLUSION: Although the MEK Inhibitor in Low-Grade Serous Ovarian Cancer Study did not meet its primary end point, binimetinib showed activity in LGSOC across the efficacy end points evaluated. A higher response to chemotherapy than expected was observed and KRAS mutation might predict response to binimetinib.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Monk BJ, Grisham RN, Banerjee S, et al. MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. J Clin Oncol. 2020. PMID: 32822286. doi:10.1200/JCO.20.01164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。